Monoclonal antibody · Agonist of CD27 · developed by Celldex Therapeutics
Varlilumab is a human agonistic monoclonal antibody that binds CD27, a co-stimulatory tumor necrosis factor family receptor on T lymphocytes, memory B cells and natural killer cells. By engaging CD27, it aims to enhance T-cell and NK cell activation and cytotoxic responses against CD27-expressing tumor cells. It is studied in glioblastoma and melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03688178 | Phase 2 | Glioblastoma | Active not recruiting | CLDX |
| NCT03617328 | Phase 1/2 | Melanoma | Completed | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
GlioblastomaMelanoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →